APG-2575 Plus Azacitidine
A Phase Ib/II Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML), Mixed Phenotype Acute Leukemia (MPAL), Chronic Myelomonocytic Leukemia (CMML) and Higher-Risk Myelodysplastic Syndrome (MDS
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1/2
- Enrollment
- 24 patients (estimated)
- Sponsors
- Ascentage Pharma Group Inc.
- Tags
- Antimetabolites, BCL-2 Inhibitor, Hypomethylating Agents (HMA)
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 1664
- NCT Identifier
- NCT04964518
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.